Candel Therapeutics(CADL) - 2025 Q4 - Annual Report

Clinical Trial Results - Aglatimagene besadenovec demonstrated a statistically significant improvement in disease-free survival (DFS) with a median DFS not reached in the treatment arm compared to 86.1 months in the placebo arm (p=0.0155; HR 0.70; 95% CI 0.52 to 0.94) in a phase 3 trial involving 745 patients[24] - The phase 3 trial showed a 67.1% rate of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) in the aglatimagene arm compared to 58.6% in the placebo arm (p=0.0164) and an 80.4% pathological complete response rate in post-treatment biopsies versus 63.6% in the control arm (p=0.0015)[24] - In a phase 2a trial for non-small cell lung cancer (NSCLC), patients treated with aglatimagene plus valacyclovir had a median overall survival (mOS) of 24.5 months, significantly longer than the historical mOS of <12 months for similar patients receiving standard care[25] - The median overall survival (mOS) for patients receiving aglatimagene in a phase 2a trial for borderline resectable pancreatic cancer was 31.4 months compared to 12.5 months in the control group[30] - Aglatimagene plus valacyclovir demonstrated a median overall survival (mOS) of 24.5 months in patients with inadequate response to immune checkpoint inhibitors (ICIs) compared to 9.8-11.8 months with standard docetaxel chemotherapy[59] - In patients with progressive disease despite ICI treatment, mOS was 21.5 months, significantly longer than historical controls[59] - In a phase 2a trial for borderline-resectable pancreatic adenocarcinoma, estimated mOS was 28.8 months for the aglatimagene group versus 12.5 months for the control group[60] - Linoserpaturev, a novel HSV-based product candidate, showed mOS of 11.8 months in recurrent high-grade glioma (HGG) patients, exceeding historical controls[63] Regulatory Designations - Aglatimagene received Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA for the treatment of newly diagnosed, localized prostate cancer in patients with intermediate- to high-risk disease[24] - Linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA for the treatment of recurrent HGG[28] - The FDA granted Fast Track Designation for aglatimagene plus valacyclovir for pancreatic cancer treatment in December 2023, and Orphan Drug Designation in April 2024[30] - The company received FDA Fast Track Designation for both aglatimagene and linoserpaturev, indicating potential for significant advancements in treatment[63][68] Future Plans and Developments - The company is preparing to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in Q4 2026, with ongoing studies to support this submission[25] - The company plans to present novel immunological biomarker data in patients with localized prostate cancer in Q3 2026[25] - A pivotal phase 3 clinical trial of aglatimagene in patients with progressive, metastatic, non-squamous NSCLC is planned to initiate in Q2 2026[30] - The company plans to announce supportive data on prostate cancer-specific outcomes in Q2 2026[106] - The company plans to initiate a pivotal phase 3 clinical trial for aglatimagene in NSCLC in Q2 2026, with updated OS data expected in Q1 2026[112] Safety and Tolerability - Aglatimagene was well tolerated, with common adverse events being mild to moderate flu-like symptoms, fever, and chills, with no increase in serious adverse events compared to placebo[24] - Aglatimagene has shown a favorable safety profile in over 1,000 patients and demonstrated activity in clinical trials across various solid tumor types, including a positive phase 3 trial in localized prostate cancer[82] - Aglatimagene has shown favorable tolerability and safety data, with most adverse events being mild to moderate in severity[105] - The company has observed a favorable safety profile for aglatimagene, with no dose-limiting toxicities reported in clinical trials[113] Market Opportunity - The market opportunity for the company's advanced clinical trials spans localized prostate cancer, NSCLC, pancreatic cancer, and recurrent HGG, indicating substantial potential for future growth[70] - The prostate cancer therapy market is projected to exceed $16.1 billion by 2026, indicating significant growth potential[71] - Approximately 300,000 men are diagnosed with prostate cancer annually in the U.S., with over 30,000 deaths each year, highlighting the medical burden[71] - Current standard of care (SoC) for intermediate- to high-risk prostate cancer patients results in disease recurrence in about 30% of cases, indicating a substantial unmet need for new treatments[72] - Aglatimagene is believed to provide a significant commercial opportunity for borderline resectable pancreatic cancer patients if it can improve overall survival compared to SoC alone[78] Competitive Landscape - The company faces competition from major pharmaceutical and biotechnology companies in developing immuno-oncology therapies, including AstraZeneca and Merck & Co.[152] - Competitors may have greater financial resources and expertise, potentially impacting the company's market position and ability to recruit qualified personnel[154] - The company could lose commercial opportunities if competitors develop safer, more effective, or less expensive products[155] Intellectual Property and Agreements - The company owns a U.S. patent and a pending U.S. patent application for its aglatimagene product candidate, with expected expiration in 2034, and additional international applications related to lung cancer and prostate cancer with expirations in 2044 and 2045 respectively[159][160] - The enLIGHTEN™ Discovery Platform has exclusive patent protection in the U.S., China, and Europe, with pending applications expected to expire in 2037 and 2043[161] - The RTW Purchase Agreement includes a $100 million payment upon FDA marketing approval of aglatimagene for prostate cancer, with a tiered royalty structure based on future net sales[124] - The company is obligated to pay royalties to MGB upon the first commercial sale of Licensed Products, with rates increasing from low single digits to high single digits as net sales increase[141] Regulatory Compliance - The company is subject to extensive regulations under the FD&C Act and PHS Act, which govern all aspects of biological product development, requiring significant time and financial resources for compliance[162][164] - The FDA's biological product licensing process involves multiple stages, including preclinical studies, IND submission, and clinical trials, with a comprehensive review of safety and efficacy required before marketing approval[165][166] - Regulatory agencies require extensive monitoring and auditing of clinical activities, with annual progress reports and safety reports mandated for submission[175] - The FDA requires biological product manufacturers to comply with cGMPs, which impose procedural and documentation requirements, necessitating ongoing investment in production and quality control[194]